Naltrexone: A Cornerstone in Medication-Assisted Treatment
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $7.14 | $214.26 (0%) | 🛒 Add to cart |
| 60 | $6.76 | $428.52 $405.49 (5%) | 🛒 Add to cart |
| 90 | $6.62
Best per pill | $642.78 $595.72 (7%) | 🛒 Add to cart |
Synonyms | |||
Naltrexone is a competitive opioid antagonist medication that represents a critical pharmacological tool in the management of both alcohol use disorder (AUD) and opioid use disorder (OUD). By selectively blocking opioid receptors in the brain, it disrupts the reinforcing cycle of addiction, effectively reducing cravings and preventing relapse. Its efficacy is well-documented in clinical trials, offering a non-addictive, long-acting option for patients committed to sustained recovery. This expert guide details its mechanism, application, and essential safety information for healthcare professionals and informed patients.
Features
- Pharmacological Class: Pure opioid receptor antagonist.
- Available Formulations: Oral tablets (50 mg standard) and extended-release intramuscular injectable suspension (380 mg/vial).
- Mechanism of Action: Competitively binds to mu-opioid receptors, blocking the euphoric and sedative effects of exogenous opioids.
- Half-Life: Oral: approximately 4-13 hours; Injectable: released over approximately 30 days.
- Metabolism: Primarily hepatic, via dihydrodiol dehydrogenase.
- Excretion: Primarily renal.
Benefits
- Craving Reduction: Significantly diminishes the intense cravings for alcohol and opioids, a primary driver of relapse.
- Relapse Prevention: Blocks the euphoric effects of opioids, removing the pharmacological reward for use and breaking the cycle of addiction.
- Non-Addictive Profile: Unlike agonist therapies (e.g., methadone, buprenorphine), naltrexone has no abuse potential, dependence liability, or associated withdrawal syndrome upon discontinuation.
- Flexible Administration: The availability of both daily oral and monthly injectable formulations allows for personalized treatment plans that enhance adherence.
- Supports Psychosocial Therapy: By managing the biological component of addiction, it allows patients to more fully engage in and benefit from concurrent counseling and behavioral therapies.
- Improves Long-Term Outcomes: Demonstrated to increase the number of abstinent days and improve overall quality of life and social functioning in compliant patients.
Common use
Naltrexone is FDA-approved for two primary indications. First, for the treatment of alcohol use disorder (AUD), where it is used to help maintain abstinence by reducing the craving for alcohol and its pleasurable effects. Second, for the prevention of relapse to opioid dependence following opioid detoxification. It is crucial that patients are fully detoxified from opioids before initiation to avoid precipitating acute withdrawal. It is used as part of a comprehensive treatment program that includes psychosocial support.
Dosage and direction
Initiation Protocol: Treatment should not be initiated until a patient is opioid-free for a minimum of 7-10 days. A naloxone challenge test may be considered to confirm the absence of physiological dependence.
- Oral Tablet (ReVia®): The recommended maintenance dose is 50 mg once daily. Some protocols utilize a flexible dosing strategy, such as 100 mg every other day or 150 mg every third day, though daily dosing is standard.
- Extended-Release Injectable (Vivitrol®): 380 mg is delivered via intramuscular gluteal injection by a healthcare professional every 4 weeks (or once monthly). The injection must be administered using the provided safety needle and must not be administered intravenously.
- Direction: Oral tablets can be taken with or without food. Adherence to the prescribed schedule is critical for efficacy, especially with the oral formulation.
Precautions
- Hepatotoxicity: Naltrexone has the potential to cause dose-related hepatocellular injury. Liver function tests (LFTs) are recommended before initiation and periodically during therapy, especially at higher-than-recommended doses.
- Depression and Suicidality: As with many treatments for addiction, patients should be monitored for the emergence or worsening of depression, suicidal ideation, or suicidal behavior.
- Opioid Tolerance: Patients must be made aware that attempting to overcome the blockade by taking large amounts of opioids is extremely dangerous and can lead to fatal respiratory depression or coma.
- Pain Management: Naltrexone blocks the effects of opioid analgesics. For patients requiring analgesia (e.g., for surgery, trauma), a non-opioid analgesic regimen must be planned. In an emergency, the blockade can be overcome with high-dose opioids under direct medical supervision, but this carries a significant risk of profound respiratory depression.
- Eosinophilic Pneumonia: There have been post-marketing reports of eosinophilic pneumonia associated with the injectable formulation; patients presenting with progressive dyspnea, hypoxia, and diffuse pulmonary infiltrates should be evaluated.
Contraindications
- Current physical dependence on opioids or acute opioid withdrawal (will precipitate severe withdrawal).
- Positive urine screen for opioids.
- Acute hepatitis or liver failure.
- History of a hypersensitivity reaction to naltrexone or any component of the formulation (e.g., polylactide-co-glycolide microspheres in Vivitrol®).
Possible side effect
Common side effects are often transient and may include:
- Nausea, vomiting, abdominal pain/cramps
- Headache, dizziness, anxiety, nervousness
- Insomnia, low energy
- Joint and muscle pain
- Injection site reactions (for Vivitrol®): pain, tenderness, induration, swelling, erythema, bruising, pruritus
Less common but more serious side effects require medical attention:
- Signs of hepatotoxicity: abdominal pain lasting more than a few days, dark urine, jaundice (yellowing of the skin or sclera)
- Signs of depression or suicidal thoughts
- Severe skin reactions or allergic reactions (e.g., rash, hives, swelling, difficulty breathing)
- Pneumonia symptoms (e.g., shortness of breath, wheezing, cough, chest pain)
Drug interaction
- Opioid-Containing Medications: Naltrexone will block the effects of opioid agonists (e.g., morphine, hydrocodone, oxycodone, codeine) and partial agonists (e.g., buprenorphine). It will also precipitate withdrawal in patients dependent on these substances.
- Opioid Antagonists: Additive effects with other antagonists (e.g., naloxone, nalmefene).
- Thioridazine: Naltrexone may increase the levels of thioridazine, potentially prolonging the QTc interval.
- Hepatotoxic Drugs: Concomitant use with other medications known to cause hepatotoxicity (e.g., certain anticonvulsants, antipsychotics) may increase the risk of liver injury.
Missed dose
- Oral Tablets: If a dose is missed, it should be taken as soon as remembered. If it is close to the time of the next dose, the missed dose should be skipped, and the regular dosing schedule resumed. Do not double the dose.
- Injectable (Vivitrol®): The next injection should be administered as soon as possible by a healthcare provider.
Overdose
There is no defined fatal dose of naltrexone itself in non-opioid-dependent individuals. Massive overdose may be associated with an increased risk of liver injury. Symptoms could include nausea, abdominal pain, dizziness, and sedation. Management is supportive and symptomatic. In a patient who has overdosed on naltrexone and then attempts to overcome the blockade with opioids, the primary medical emergency is the opioid overdose, which must be treated aggressively with naloxone; however, larger-than-usual doses and continuous infusion may be required due to naltrexone’s competitive blockade.
Storage
- Oral Tablets: Store at room temperature (20°-25°C or 68°-77°F) in a tight, light-resistant container. Keep out of reach of children and pets.
- Injectable (Vivitrol®): The kit must be refrigerated (2°-8°C or 36°-46°F) but can be kept at room temperature for no more than 7 days prior to mixing. Once mixed, the suspension must be administered immediately. Do not freeze.
Disclaimer
This information is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned.
Reviews
- Clinical Consensus: Naltrexone is widely regarded by addiction specialists as a vital, evidence-based component of a modern MAT program. Its role in reducing cravings is particularly praised.
- Patient Feedback: Reviews are often mixed and highly dependent on formulation and adherence. Patients who successfully complete detox and consistently take the medication (especially the injectable form) frequently report dramatically reduced cravings and a newfound sense of control. A common challenge noted with the oral formulation is difficulty with daily adherence. Some patients report initial side effects like nausea, which often subside.
- Overall: Efficacy is strongly correlated with patient motivation, a robust support system, and integration with behavioral therapy. It is not a “magic bullet” but a powerful tool for those committed to recovery.